SCHEMBL1928394

SCHEMBL1928394

N[C@H](Cc1c[nH]c2ccccc12)c1nc(-c2ccccc2)c[nH]1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR1 P30872 2/20 0.63
HTR2A P28223 2/20 0.52
ADRB1 P08588 1/20 0.52
HTR1A P08908 1/20 0.52
ADRA2A P08913 1/20 0.52
SLC6A2 P23975 1/20 0.52
HTR1D P28221 1/20 0.52
HTR1B P28222 1/20 0.52
HTR2C P28335 1/20 0.52
HTR1E P28566 1/20 0.52
SLC6A4 P31645 1/20 0.52
HTR7 P34969 1/20 0.52
HTR2B P41595 1/20 0.52
HTR6 P50406 1/20 0.52
SLC6A3 Q01959 1/20 0.52
KDM4E B2RXH2 5/20 0.51
MAPT P10636 3/20 0.51
TSHR P16473 2/20 0.51
MEN1 O00255 1/20 0.51
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4244351 1.00 SSTR1 (0.63) SSTR1HTR2AADRB1HTR1AADRA2A
SCHEMBL6430387 1.00 SSTR1 (0.63) SSTR1HTR2AADRB1HTR1AADRA2A
Hydrochloric Acid SCHEMBL6723717 0.99 SSTR1 (0.62) SSTR1HTR2AADRB1HTR1AADRA2A
Hydrochloric Acid SCHEMBL27472186 0.99 SSTR1 (0.62) SSTR1HTR2AADRB1HTR1AADRA2A
Hexane SCHEMBL27589497 0.93 SSTR1 (0.56) SSTR1HTR2AADRB1HTR1AADRA2A
SCHEMBL3012885 0.90 SSTR1 (0.53) SSTR1HTR2AADRB1HTR1AADRA2A
Hydrochloric Acid SCHEMBL27542605 0.90 SSTR1 (0.53) SSTR1HTR2AADRB1HTR1AADRA2A
Hydrochloric Acid SCHEMBL1723213 0.90 SSTR1 (0.53) SSTR1HTR2AADRB1HTR1AADRA2A
SCHEMBL13244865 0.90 SSTR1 (0.53) SSTR1HTR2AADRB1HTR1AADRA2A
Hydrochloric Acid SCHEMBL3019998 0.89 SSTR1 (0.52) SSTR1HTR2AADRB1HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146627-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments LASSAUNIERE PIERRE-ETIENNE CHA 2008-06-19 US claimed
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2007-02-08 US claimed
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments IPSEN PHARMA S.A.S. (FR) 2005-02-17 US claimed
US-20040132788-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-08 US claimed
EP-1305294-A2 IMIDAZOLYL DERIVATIVES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2003-05-02 EP claimed
CN-1391474-A 5-membered heterocyclic derivatives, their preparation and their use as medicaments SOD CONSEILS RECH APPLIC (FR) 2003-01-15 CN claimed
EP-1228760-A2 5-membered heterocycle derivatives, production thereof and use thereof as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-08-07 EP claimed
WO-2002010140-A2 IMIDAZOLYL DERIVATIVES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-02-07 WO claimed
US-20200360483-A1 METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE IPSEN PHARMA S.A.S. (FR) 2020-11-19 US disclosed
US-20200347110-A1 Composition and Methods for Stimulating Gastrointestinal Motility IPSEN PHARMA S.A.S. (FR) 2020-11-05 US disclosed
US-20190248861-A1 Composition and Methods for Stimulating Gastrointestinal Motility IPSEN PHARMA S.A.S. (FR) 2019-08-15 US disclosed
EP-1937262-B1 COMPOSITION FOR USE IN TREATING GASTROINTESTINAL DYSMOTILITY IPSEN PHARMA (FR) 2019-05-08 EP disclosed
US-20170362275-A1 Growth Hormone Releasing Peptides IPSEN PHARMA S.A.S. (FR) 2017-12-21 US disclosed
US-20170304403-A1 METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE IPSEN PHARMA S.A.S. (FR) 2017-10-26 US disclosed
WO-2002010140-A2 IMIDAZOLYL DERIVATIVES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-02-07 WO disclosed
CN-1319094-A Imidazolyl derivatives SOD CONSEILS RECH APPLIC (FR) 2001-10-24 CN disclosed
EP-1086086-A1 IMIDAZOLYL DERIVATIVES AND THEIR USE AS SOMATOSTATIN RECEPTOR LIGANDS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 2001-03-28 EP disclosed
EP-1086101-A1 BETA-CARBOLINE COMPOUNDS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 2001-03-28 EP disclosed
WO-1999064420-A1 β-CARBOLINE COMPOUNDS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S (FR) 1999-12-16 WO disclosed
WO-1999064401-A2 IMIDAZOLYL DERIVATIVES AND THEIR USE AS SOMATOSTATIN RECEPTOR LIGANDS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS (FR) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304403-A1 METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE PROKR1, CCL2, PROKR2 SSTR1 274/4885HTR2A 872/4885ADRB1 1076/4885
US-20200360483-A1 METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE PROKR1, CCL2, PROKR2 SSTR1 274/4885HTR2A 872/4885ADRB1 1076/4885
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OXER1, OPRL1, OPRK1 SSTR1 1981/4885HTR2A 835/4885ADRB1 151/4885
US-20040132788-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OPRK1, HCN1, P2RX7 SSTR1 1927/4885HTR2A 665/4885ADRB1 93/4885
US-20080146627-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OXER1, OPRL1, P2RX7 SSTR1 2451/4885HTR2A 1364/4885ADRB1 269/4885
US-20170362275-A1 Growth Hormone Releasing Peptides GHRHR, THRB, PRLHR SSTR1 40/4885HTR2A 409/4885ADRB1 237/4885
US-20190248861-A1 Composition and Methods for Stimulating Gastrointestinal Motility GIPR, VIP, GRPR SSTR1 36/4885HTR2A 690/4885ADRB1 1320/4885
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. GHSR, IGF1R, GIPR SSTR1 4/4885HTR2A 296/4885ADRB1 31/4885
US-20200347110-A1 Composition and Methods for Stimulating Gastrointestinal Motility GIPR, VIP, GRPR SSTR1 36/4885HTR2A 690/4885ADRB1 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.